Anlon HealthcareNSE:AHCL 17 Gross Margin % is 45.28% as of Mar. 2026, which is 19% above its 10-year median of 37.99. GuruFocus rates NSE:AHCL with a GF Score™ of 17/100. The stock has 5 warning signs investors should review. Among 937 Drug Manufacturers companies, Anlon Healthcare ranks worse than 61.79% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Anlon Healthcare had a gross margin of 45.28% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Anlon Healthcare Gross Margin % Related Terms
Anlon Healthcare Gross Margin % Historical Data
* Premium members only.
The historical data trend for Anlon Healthcare's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Anlon Healthcare's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anlon Healthcare Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anlon Healthcare's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Anlon Healthcare's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Anlon Healthcare (NSE:AHCL) has a Gross Margin % of 45.28% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Anlon Healthcare and its competitors. This is 19% above median its historical median of 37.99. Over the past decade, Anlon Healthcare's Gross Margin % has ranged from 21.68 to 45.26. According to the industry distribution chart, Anlon Healthcare ranks #579 out of 937 companies in the Drug Manufacturers industry, placing it in the top 61.8%.
Is Anlon Healthcare's Gross Margin % too high?
Anlon Healthcare's current Gross Margin % of 45.28% is 19% above median its 10-year median of 37.99. Over the past 10 years, this metric has ranged from a low of 21.68 to a high of 45.26. The Drug Manufacturers industry median Gross Margin % is 48.46. Anlon Healthcare's value of 45.28% is 6.6% below this industry median. Based on the distribution chart, Anlon Healthcare ranks #579 out of 937 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Anlon Healthcare has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Anlon Healthcare's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Anlon Healthcare ranks #579 out of 937 companies for Gross Margin %. This places Anlon Healthcare in the lower half of its industry. The industry median Gross Margin % is 48.46. Anlon Healthcare's value of 45.28% is 6.6% below this benchmark. Historically, Anlon Healthcare's own Gross Margin % has ranged from 21.68 to 45.26 over the past decade. While the company's 10-year median is 37.99 vs. the industry median of 48.46, Anlon Healthcare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.46, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anlon Healthcare's current Gross Margin % of 45.28% is 6.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Anlon Healthcare and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anlon Healthcare's current Gross Margin % is 45.28%, which is 19% above median its own 10-year median of 37.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anlon Healthcare stock overvalued right now?
Anlon Healthcare (NSE:AHCL) has a current Gross Margin % of 45.28%. The current Gross Margin % is 45.28%, which is 19% above median its 10-year median of 37.99 and 6.6% below the Drug Manufacturers industry median of 48.46. Anlon Healthcare's overall GF Score™ is 17/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Anlon Healthcare (NSE:AHCL), the current Gross Margin % is 45.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anlon Healthcare Ltd is a chemical manufacturing company engaged in manufacturing of; (i) high purity advance pharmaceutical intermediates which serves as raw material/ key starting material in the manufacturing of active pharmaceutical ingredients; and (ii) active pharmaceutical ingredients which serves as a raw material for pharmaceutical formulations in preparation of various type of Finished Dosage Formula such as tablet, capsules, ointment, syrup etc, ingredients in nutraceuticals formulations, personal care products and animal health products. Its products spans across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API.
17GF Score
Get the complete analysis for NSE:AHCL
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AHCL has been successfully added to your 
